Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBT (2016 - 2026)

Insight Molecular Diagnostics' EBT history spans 6 years, with the latest figure at -$23.4 million for Q4 2025.

  • On a quarterly basis, EBT rose 30.31% to -$23.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$51.1 million, a 16.06% increase, with the full-year FY2025 number at -$51.1 million, up 16.25% from a year prior.
  • EBT hit -$23.4 million in Q4 2025 for Insight Molecular Diagnostics, down from -$11.0 million in the prior quarter.
  • Over the last five years, EBT for IMDX hit a ceiling of $6.0 million in Q1 2023 and a floor of -$35.8 million in Q4 2021.
  • Historically, EBT has averaged -$11.4 million across 5 years, with a median of -$10.4 million in 2025.
  • The widest YoY moves for EBT: up 274.6% in 2023, down 510.92% in 2023.
  • Tracing IMDX's EBT over 5 years: stood at -$35.8 million in 2021, then surged by 66.42% to -$12.0 million in 2022, then tumbled by 33.08% to -$16.0 million in 2023, then crashed by 110.27% to -$33.6 million in 2024, then surged by 30.31% to -$23.4 million in 2025.
  • Business Quant data shows EBT for IMDX at -$23.4 million in Q4 2025, -$11.0 million in Q3 2025, and -$9.8 million in Q2 2025.